HAEMATOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

ALLG CML8 TWISTER

Protocol Title

A Phase 2 study of withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission

ALLG M13

High Dose Cytarabine and Fludarabine Without Anthracycline for Patients with Core Binding Factor Acute Myeloid Leukaemia

ALLG MDS4

A Randomised Phase 2 Study Comparing the Efficacy of 5-Azacitidine Alone versus Combination Therapy with Lenalidomide and 5-Azacitidine in Patients with Higher Risk Myelodysplastic Syndromes (Mds) and Low Marrow Blast Count Acute Myeloid Leukaemia (Aml)

ALLG MM14

A Prospective Randomised Phase 2 Study of Single Agent Pomalidomide Maintenance versus Combination Pomalidomide and Low Dose Dexamethasone Maintenance following Induction with the Combination of Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed and Refractory Myeloma Previously Treated with Lenalidomide

ALLG MM17

A Multicentre Single Arm Study of Carfilzomib-Thalidomide-Dexamethasone (CarTD) for Newly Diagnosed Transplant-Eligible Multiple Myeloma (TE NDMM) Patients Refractory to Initial Bortezomib-Based Induction Therapy

ALLG NHL16 PRIMA A Multicentre, Phase 3, Open-Label, Randomized Study in Patients with Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy with Rituximab (MabThera(R)) After Induction Of Response with Chemotherapy Plus Rituximab In Comparison with No Maintenance Therapy

ALLG NHL33 WAMM

An ALLG Window Study of Acalabrutinib plus Rituximab followed by R-DHAOx+ASCT in fit Mantle Cell Lymphoma

AMARC_03-16

A Randomized Phase 2 Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) compared with VCD and Daratumumab Induction followed by Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant Ineligible Patients with Multiple Myeloma

BGB-3111-212

Rosewood An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma

BGB-3111-212

Rosewood An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma